Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT06029127 |
| Consolidated Lead Sponsor | BeiGene |
| Therapeutic Condition Cohort | Oncology and Hematology |
| Clinical Trial Phase | Phase II |
| Overall Recruitment Status | COMPLETED |
| Registered Enrollment | 35 participants (ACTUAL) |
| Registered Start Date | 2023-10-23 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| Cancer Hospital Chinese Academy of Medical Sciences | Beijing, China | Open Hospital Dossier -> |
| Harbin Medical University Cancer Hospital | Harbin, China | Open Hospital Dossier -> |
| Henan Cancer Hospital | Zhengzhou, China | Open Hospital Dossier -> |
| The Second Xiangya Hospital of Central South University | Changsha, China | Open Hospital Dossier -> |
Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.